Neomorph, a San Diego-based biotech founded by Philip Chamberlain in 2020, is rapidly advancing in the field of molecular glue technology, raising over $200 million in private venture capital and expanding its workforce to over 80 researchers. The company’s lead drug candidate, NEO-811, is currently in Phase 1/2 clinical trials for cancer, marking a significant step in harnessing molecular glues to target previously difficult proteins. Neomorph has partnered with major pharmaceutical companies such as AbbVie and Biogen, highlighting its platform’s capacity to engineer solutions across various diseases, and has recently signed a lease for an 80,000-square-foot lab facility in Sorrento Mesa to support its ongoing growth.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://businessofsandiego.substack.com/p/exclusive-inside-neomorphs-rise-during
